Gadolinium is a contrast agent used in MRI, not recommended in pregnancy. According to a study by Dr. Steven Bird, more and more women in the early stages of gestation are instead exposed to this substance.
The results could prevent many of these cases, which usually occur when the woman does not yet know she is pregnant. About 45% of US MRIs use gadolinium as a contrast agent. Recent studies show that the body could retain part of the substance even after analysis, with consequences that are currently unclear.
Gadolinium can cross the placenta barrier and enter the fetus's body. Doctors do not yet know how this could affect development; according to some studies, gadolinium could have negative consequences on the fetus. As a result, doctors advise against the use of the substance by pregnant women.
The only exception is when the life of a woman and a child are in danger and MRI is absolutely necessary. The researchers analyzed data collected from 16 FDA's Sentinel System partners, a medical questionnaire program. Out of 4,692,744 newborns, 5,457 were exposed to the substance in the prenatal phase.
The number corresponds to about 1 child every 860 pregnancy. Most cases are related to head, pelvis and abdomen analysis. About 3 cases out of 4 occur in the very early stages of the first trimester, when the woman does not know she is pregnant. The authors of the study suggest submitting a questionnaire to women of childbearing age who need to do a resonance. This way you could ask them if there is the possibility that they are pregnant and, if so, consider alternatives.